Evidence map›Paper›PMID 41291616›Full record

ArticleBMC cancer2025

Impact of comorbidities on survival in melanoma patients.

Alessandra Buja, Fortunato Cassalia, Massimo Rugge, Chiara Trevisiol, Manuel Zorzi, Paolo Del Fiore, Ilaria Pantaleo, Carlo Riccardo Rossi, Pierfranco Conte, Anna Belloni Fortina and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alessandra BujaDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Via Loredan 18, Padua, 35131, Italy.
Fortunato CassaliaDepartment of Medicine - DIMED, Dermatology Unit, University of Padova, Via Gabelli 61, Padua, 35121, Italy.
Massimo RuggeDepartment of Medicine - DIMED, Pathology and Cytopathology Unit, University of Padova, Via Gabelli 61, Padua, 35121, Italy.
Chiara TrevisiolSoft-Tissue, Peritoneum, and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV- IRCCS, Via Gattamelata 64, Padua, 35128, Italy. chiara.trevisiol@iov.veneto.it.
Manuel ZorziVeneto Tumour Registry (RTV), Azienda Zero, Via Jacopo Avanzo 35, Padua, 35132, Italy.
Paolo Del FioreSoft-Tissue, Peritoneum, and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV- IRCCS, Via Gattamelata 64, Padua, 35128, Italy.
Ilaria PantaleoDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Via Loredan 18, Padua, 35131, Italy.
Carlo Riccardo RossiDepartment of Surgery, Oncology, and Gastroenterology - DISCOG, University of Padova, Via Giustiniani 2, Padua, 35128, Italy.
Pierfranco ConteSan Camillo IRCCS Hospital, Via Alberoni 70, Venice, 30126, Italy.
Anna Belloni FortinaDepartment of Women's and Children's Health (SDB), Pediatric Dermatology Regional Center, University of Padova, Via Giustiniani 3, Padua, 35128, Italy.
Simone MocellinSoft-Tissue, Peritoneum, and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV- IRCCS, Via Gattamelata 64, Padua, 35128, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increasing incidence of cutaneous melanoma (CM) is a significant public health issue. However, few studies have focused on how comorbidity patterns may influence the outcomes of CM patients. This study aimed to identify comorbidity patterns among CM patients and assess their impact on survival rates.

methodsThis retrospective population-based cohort study included all CM patients recorded in the regional Veneto Cancer Registry in 2019 and 2021. Comorbidity data (ICD-9-CM coding) were obtained from hospital discharge records and included 17 primary disease categories. Patients with at least two documented conditions were clustered via latent class analysis (LCA), with the optimal number of clusters determined via the Akaike information criterion (AIC).

resultsThis population-based retrospective cohort study included 2,114 CM patients. Coexisting medical conditions were documented in 1,048 (49.6%) patients; multiple conditions were documented in 19.9% of the study cohort. Among these patients, the LCA identified three patterns: (1) cardio-endocrine-respiratory (20.96%); (2) pregnancy-psychosocial (29.97%); and (3) injury-multiorgan-multifactorial disorders (49.08%). Patients in the injury-multiorgan-multifactorial class had the highest mortality risk (HR = 3.08, 95% CI: 2.25-4.22).

conclusionsComorbidity class has a significant effect on the survival of CM patients. The incorporation of the comorbidity profile into clinical care strategies can improve prognostic accuracy and enhance patient management.

Indexed as

MelanomaSkin NeoplasmsAdultAgedAged, 80 and overComorbidityCutaneous Malignant MelanomaFemaleHumansMaleMiddle AgedRegistriesRetrospective StudiesSurvival RateYoung AdultCancer registryCohort studyHealth care resourcesHealth care services: comorbidityMelanomaSurvival

Identifiers

PMID41291616
PMCPMC12771939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.